Your browser doesn't support javascript.
Practice of adjunctive treatments in critically ill COVID-19 patients-rational for the multicenter observational PRoAcT-COVID study in The Netherlands.
Valk, Christel M A; Swart, Pien; Boers, Leonoor S; Botta, Michela; Bos, Lieuwe D J; de Abreu, Marcelo Gama; Hol, Liselotte; Hollmann, Markus W; Horn, Janneke; Martin-Loeches, Ignacio; Mazzinari, Guido; Myatra, Sheila N; Nijbroek, Sunny G; Rosenberg, Neeltje M; Stilma, Willemke; Tsonas, Anissa M; van der Ven, Ward H; Neto, Ary Serpa; Schultz, Marcus J; Paulus, Frederique.
  • Valk CMA; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Swart P; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Boers LS; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Botta M; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Bos LDJ; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • de Abreu MG; Department of Anesthesiology and Intensive Care, Pulmonary Engineering Group, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Hol L; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Hollmann MW; Department of Anesthesiology, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Horn J; Department of Anesthesiology, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Martin-Loeches I; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Mazzinari G; Department of Clinical Medicine, St. James's Hospital, Dublin, Ireland.
  • Myatra SN; Department of Anaesthesiology, Hospital Universitario y Politécnico la Fe, Valencia, Spain.
  • Nijbroek SG; Department of Intensive Care, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
  • Rosenberg NM; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Stilma W; Department of Anesthesiology, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Tsonas AM; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • van der Ven WH; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Neto AS; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Schultz MJ; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
  • Paulus F; Department of Intensive Care, Amsterdam UMC, location 'AMC', Amsterdam, The Netherlands.
Ann Transl Med ; 9(9): 813, 2021 May.
Article in English | MEDLINE | ID: covidwho-1257379
ABSTRACT

BACKGROUND:

Patients with coronavirus disease 2019 (COVID-19) may need hospitalization for supplemental oxygen, and some need intensive care unit (ICU) admission for escalation of care. Practice of adjunctive and supportive treatments remain uncertain and may vary widely between countries, within countries between hospitals, and possibly even within ICUs. We aim to investigate practice of adjunctive and supportive treatments, and their associations with outcome, in critically ill COVID-19 patients.

METHODS:

The 'PRactice of Adjunctive Treatments in Intensive Care Unit Patients with Coronavirus Disease 2019' (PRoAcT-COVID) study is a national, observational study to be undertaken in a large set of ICUs in The Netherlands. The PRoAcT-COVID includes consecutive ICU patients, admitted because of COVID-19 to one of the participating ICUs during a 3-month period. Daily follow-up lasts 28 days. The primary endpoint is a combination of adjunctive treatments, including types of oxygen support, ventilation, rescue therapies for hypoxemia refractory to supplementary oxygen or during invasive ventilation, other adjunctive and supportive treatments, and experimental therapies. We will also collect tracheostomy rate, duration of invasive ventilation and ventilator-free days and alive at day 28 (VFD-28), ICU and hospital length of stay, and the mortality rates in the ICU, hospital and at day 90.

DISCUSSION:

The PRoAcT-COVID study is an observational study combining high density treatment data with relevant clinical outcomes. Information on treatment practices, and their associations with outcomes in COVID-19 patients in highly and urgently needed. The results of the PRoAcT-COVID study will be rapidly available, and circulated through online presentations, such as webinars and electronic conferences, and publications in peer-reviewed journals-findings will also be presented at a dedicated website. At request, and after agreement of the PRoAcT-COVID steering committee, source data will be made available through local, regional and national anonymized datasets. TRIAL REGISTRATION The PRoAcT-COVID study is registered at clinicaltrials.gov (study identifier NCT04719182).
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Language: English Journal: Ann Transl Med Year: 2021 Document Type: Article Affiliation country: Atm-21-764

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Language: English Journal: Ann Transl Med Year: 2021 Document Type: Article Affiliation country: Atm-21-764